Secretome Platform
The facility
The secretome represents up to 30% of the whole proteome and includes cytokines, chemokines, hormones, antibodies, interferons, growth factors, which are involved in essential biological process. These proteins can be measured in serum, plasma, stool and saliva samples both in human and mouse, and in culture medium using the Luminex® 200™ System (Luminex Corporation, Austin, TX, USA), a flexible analyzer based on the principles of flow cytometry that allows to measure simultaneously (multiplexing) up to 100 analytes in a single microplate well, using very small samples.
Current applications:
- Understanding the biological factors that drive the progression to NASH and beyond for risk stratification and therapy through the investigation of the complex inflammatory signature underlying the onset and progression of NAFLD using a high-throughput technology.
- Discovering new potential biomarkers for the stratification of the risk of HCC development in patients with liver cirrhosis under surveillance, and for outcome prediction in patients with a diagnosis of advanced HCC undergoing systemic therapies.
- Discovering new potential biomarkers for the selection of the more appropriate therapeutic approach in patients with IBD, and for the prediction of clinical response to biologic therapy.
Prof. Elisabetta Bugianesi, MD, Ph.D. Full Professor
Dept. of Medical Sciences, Via San Massimo 24 -10123 Torino
Phone: +39 0116333541
Fax +39 0116333976
Gian Paolo Caviglia, MsC, Ph.D Assistant Professor
Dept. of Medical Sciences, Via San Massimo 24 -10123 Torino
Phone: +39 0116333922
Chiara Rosso, MsC Research Technician
Dept. of Medical Sciences, Via San Massimo 24 -10123 Torino
Tel. +39 0116333532
Bio-Plex platform is located at the Molecular Gastroenterology and Hepatology lab. (SGAS), Via San Massimo 24 – floor 4. To plan an experiment, please send an e-mail to: chiara.rosso@unito.it and gianpaolo.caviglia@unito.it
- Caviglia GP, Rosso C, Stalla F, et al. On-treatment decrease of serum interleukin-6 as a predictor of clinical response to biologic therapy in patients with inflammatory bowel diseases. J Clin Med. 2020;9(3):800. doi: 10.3390/jcm9030800
- Bertani L, Caviglia GP, Antonioli L, et al. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med. 2020;9(5):1323. doi: 10.3390/jcm9051323
In aggiornamento